The global anticoagulants market is experiencing steady growth as cardiovascular diseases, aging populations, and increasing awareness of blood clot prevention continue to drive demand for effective therapies. Anticoagulants, commonly known as blood thinners, play a critical role in preventing and treating conditions such as atrial fibrillation, deep vein thrombosis (DVT), pulmonary embolism (PE), and stroke. As healthcare systems increasingly focus on preventive care and long-term disease management, the demand for advanced anticoagulant therapies continues to expand.

Key Market Highlights

• The global anticoagulants market was valued at USD 37.3 billion in 2025. 

• The market is projected to grow from USD 38.9 billion in 2026 to USD 55.7 billion by 2033. 

• The market is expected to register a CAGR of 5.3% from 2026 to 2033. 

• The Novel Oral Anticoagulants (NOACs) segment dominated the market, accounting for 57.1% of the global revenue share in 2025. 

• The oral route of administration segment led the market with a 67.7% revenue share in 2025. 

• The atrial fibrillation and myocardial infarction application segment accounted for 34.7% of the global market revenue in 2025. 

• North America dominated the global anticoagulants market, accounting for 50.9% of the revenue share in 2025. 

• The Asia Pacific market is expected to witness the fastest growth during the forecast period, driven by expanding healthcare infrastructure and increasing cardiovascular disease prevalence. 

Download a free sample copy of the Anticoagulants Market report to understand detailed coverage and inclusions in the final report

Rising Cardiovascular Diseases Are Driving Market Growth

Cardiovascular diseases remain one of the leading causes of mortality worldwide, creating consistent demand for effective anticoagulant therapies. Conditions such as atrial fibrillation, deep vein thrombosis, pulmonary embolism, and stroke require long-term anticoagulant treatment to prevent clot formation and reduce serious complications.

Lifestyle-related factors, including physical inactivity, obesity, unhealthy diets, and aging populations, continue to increase the incidence of these disorders. Venous thromboembolism (VTE), which includes DVT and PE, affects hundreds of thousands of patients every year, making anticoagulant therapy an essential component of modern cardiovascular treatment. These trends continue to strengthen the long-term outlook for the market. 

Innovation Is Transforming Anticoagulant Therapy

The anticoagulants market has evolved significantly over the past decade. Traditional therapies such as vitamin K antagonists have gradually been complemented by newer treatment options that offer greater convenience and improved clinical outcomes.

Novel Oral Anticoagulants (NOACs) have become increasingly preferred due to their predictable therapeutic effects, fixed dosing schedules, fewer dietary restrictions, and reduced need for continuous monitoring. Healthcare providers are rapidly adopting these therapies for long-term management of cardiovascular disorders.

In addition, pharmaceutical companies continue to invest heavily in research and development to introduce safer therapies with improved efficacy. New diagnostic technologies and coagulation testing solutions are also helping physicians optimize treatment decisions and personalize patient care. 

Novel Oral Anticoagulants Lead the Market

Among all drug categories, Novel Oral Anticoagulants (NOACs) represented the largest market segment, accounting for 57.1% of global revenue in 2025. Their widespread adoption is largely attributed to improved patient convenience, lower drug interactions, and enhanced safety profiles compared to conventional anticoagulants.

Growing awareness among physicians, favorable clinical guidelines, and increasing acceptance across both developed and emerging healthcare markets continue to accelerate demand for NOACs. Ongoing product development and regulatory approvals are expected to further strengthen this segment throughout the forecast period. 

Oral Administration Remains the Preferred Choice

The route of administration significantly influences patient compliance and treatment success. In 2025, oral anticoagulants accounted for 67.7% of total market revenue, making them the dominant administration route.

Patients requiring long-term anticoagulation therapy generally prefer oral medications because they eliminate the need for frequent injections and simplify treatment management. Improved convenience has resulted in higher adherence rates, particularly among elderly patients managing chronic cardiovascular conditions.

Meanwhile, injectable anticoagulants continue to maintain an important role in hospital settings, emergency care, and acute treatment, particularly for patients requiring rapid anticoagulation. 

Atrial Fibrillation Continues to Generate Strong Demand

Based on application, the Atrial Fibrillation and Myocardial Infarction segment accounted for 34.7% of market revenue in 2025, making it the leading therapeutic application.

Atrial fibrillation significantly increases the risk of stroke due to irregular heart rhythms that promote blood clot formation. As diagnosis rates continue to rise globally, healthcare professionals increasingly prescribe anticoagulants as part of long-term disease management.

The growing prevalence of deep vein thrombosis and pulmonary embolism is also contributing to higher demand, supported by improved diagnosis and broader treatment accessibility across healthcare systems. 

Looking for more specific insights? Customize this report to suite your business needs

North America Maintains Market Leadership

Regional market performance continues to reflect healthcare infrastructure, disease prevalence, and pharmaceutical innovation.

North America dominated the global anticoagulants market with a 50.9% revenue share in 2025. The region benefits from advanced healthcare systems, high awareness of cardiovascular disease prevention, extensive adoption of novel oral anticoagulants, and strong investments by leading pharmaceutical companies.

The United States remains the largest contributor within the region, supported by widespread diagnosis of cardiovascular disorders and continuous introduction of innovative therapies. 

Asia-Pacific Emerges as the Fastest-Growing Region

While North America currently leads the market, Asia-Pacific is expected to register the fastest growth throughout the forecast period.

Rapid urbanization, expanding healthcare infrastructure, increasing healthcare expenditure, and improved access to cardiovascular treatment are creating substantial opportunities across countries including China, India, Japan, and South Korea.

Growing awareness regarding stroke prevention and improved availability of modern anticoagulant therapies are expected to further accelerate regional market expansion. 

Competitive Landscape Focuses on Innovation

Competition within the anticoagulants market remains strong as leading pharmaceutical companies continue to invest in new drug development, strategic collaborations, clinical research, and product launches.

Major companies operating in the market include Pfizer Inc., Bristol-Myers Squibb Company, Bayer AG, Sanofi, Boehringer Ingelheim International GmbH, Johnson & Johnson Services, Inc., Aspen Holdings, DAIICHI SANKYO COMPANY, LIMITED, GSK plc, and Eisai Co., Ltd. Their continued focus on innovation is expected to support the introduction of safer and more effective anticoagulant therapies over the coming years. 

Future Outlook

The anticoagulants market is expected to experience stable long-term growth as cardiovascular diseases continue to pose major healthcare challenges worldwide. Rising aging populations, increasing diagnosis of thromboembolic disorders, and growing adoption of advanced oral anticoagulants will remain key growth drivers.

Continued pharmaceutical innovation, expanding healthcare access, and improvements in personalized treatment strategies are expected to enhance patient outcomes while supporting sustained market expansion through 2033. As healthcare systems increasingly emphasize preventive cardiovascular care, anticoagulants will continue to play a crucial role in reducing disease burden and improving quality of life worldwide.

Explore our dedicated business services:

• Brainshare Consulting – End-to-end business consulting services including Opportunity assessment, GTM support, Competitive intelligence, and Consumer Analytics.

• Custom Research – Get a market intelligence report tailored to your specific requirements and aligned with your business goals.

• Consumer Insights – Capture real, evolving consumer sentiment and behavior to help you make data driven strategies.

• Horizon Databooks – Access the world’s largest portal of Market Reports & Statistics

• Investment Insights – Make investment decisions with data driven insights, powered by domain and technology

• Signal (Pricing Intelligence) - Commodity price intelligence to drives strategic advantage.

About us: 

Grand View Research, a market research and consulting company, provides syndicated research reports, customized research reports, and consulting services. Grand View Research database is used by the world's renowned academic institutions and Fortune 500 companies to understand the global and regional business environment. Our database features thousands of statistics and in-depth analysis on 46 industries in 25 major countries worldwide.